Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI

NCT00835848 on ClinicalTrials.gov · last registry update 2015-05-05

Finished December 2009, after enrolling 100 people. Primary outcome, as filed: Infarct size by MRI. exenatide is approved in the US, but not for cardiovascular disease — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: Copenhagen University Hospital, Rigshospitalet
Sponsor type: Other
Enrollment: 100
Started: 2009-01
Primary completion: 2009-12 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Infarct size by MRI

Conditions studied

Myocardial Infarction

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.